Information Provided By: 
Fly News Breaks for October 18, 2016
CELG
Oct 18, 2016 | 10:47 EDT
Piper Jaffray analyst Joshua Schimmer says that while the Phase II study of Celgene's GED-0301 for Crohn's Disease is "perhaps encouraging," a larger, placebo controlled trial is needed to have confidence in the program. GED-0301 remains "interesting but risky," Schimmer adds, while pointing out the drug is not in his model at this time. He reiterates an Overweight rating on Celgene.
News For CELG From the Last 2 Days
There are no results for your query CELG
